Picture EBD Group Global Partnering Four Events One Price 650x80
Document › Details

Biotechpharma UAB. (10/3/18). "Press Release: Biotechpharma UAB Is Changing Its Management Structure and Appoints Giedrius Žunda as Chief Executive Officer".

Organisations Organisation Biotechpharma UAB
  Group Northway (Group)
  Organisation 2 Sicor Biotech UAB
  Group Teva (Group)
Products Product contract manufacturing (biologicals)
  Product 2 biopharmaceutical
Persons Person Žunda, Giedrius (Northway 201812– CEO of Biotechpharma UAB before Sicor Biotech UAB/Teva since 2002)
  Person 2 Bumelis, Vladas Algirdas (Northway 201812– Board Chairman of Biotechpharma UAB before CEO + Founder of Biotechpharma)

Biotechpharma UAB, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, is pleased to announce the appointment of Giedrius Žunda as Chief Executive Officer effective from 3 December 2018.

Mr. G. Žunda has more than 16 years of experience with Sicor Biotech UAB, leading biotech company in Central and Eastern Europe, and Teva Pharmaceutical Industries Ltd, the largest generic company in the world. He began his career with Sicor Biotech in 2002 as Process Development Manager and with Teva in 2004, steadily advancing within the organization and most recently serving as Site General Manager of Biologics Plant and member of the Board of Sicor Biotech UAB, Teva’s Lithuanian subsidiary. Prior to joining Teva, he worked for Biocentras UAB, a biotech company, developing cleaning agents and OTC products. Mr. G. Žunda earned a master’s degree from Vilnius Gediminas Technical University.

Dr. Vladas Algirdas Bumelis, the CEO and the founder of Biotechpharma, commented: “I’m pleased to announce the appointment of Giedrius, who is my student and long-term ally, as Chief Executive Officer. He is an experienced, well-respected and talented executive. Giedrius brings a strong track record of operational excellence, strategic growth, people leadership and biologics manufacturing and supply chain management. We are confident that his leadership style and industry and operational expertise are the right fit for Biotechpharma.”

Commenting on the opportunities ahead for Biotechpharma, Mr. G. Žunda said: “I am excited to be given this opportunity at Biotechpharma. I look forward to working with Biotechpharma’s experienced management team, who have been instrumental in positioning the company’s CDMO business to capitalize on current trends in the market. I see a great opportunity to leverage the company’s vertically integrated business model and to lead its talented employees to deliver increased value for shareholders. I look forward to leading this organization to its next stage of evolution.”

Dr. V.A. Bumelis will resign as the CEO as from 3 December 2018 and will take up the position of the Chairman of the Board of Directors of Biotechpharma. He will ensure smooth management transition and oversee the business, focusing more on strategic development of the company, increasing its projects portfolio and making the company a larger player on the internanational stage.

Record changed: 2019-05-04


Picture [iito] Made Without Love 650x80px

More documents for Northway (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Network in German Capital Region 650x80px

» top